Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC reduced its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 11.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,961 shares of the company’s stock after selling 4,392 shares during the quarter. Guggenheim Capital LLC’s holdings in Revolution Medicines were worth $1,529,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. IFP Advisors Inc purchased a new position in shares of Revolution Medicines in the fourth quarter worth about $34,000. Sterling Capital Management LLC lifted its stake in Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock valued at $86,000 after acquiring an additional 1,672 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock valued at $90,000 after acquiring an additional 1,613 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Revolution Medicines by 521.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company’s stock worth $165,000 after acquiring an additional 3,178 shares during the period. Finally, Avanza Fonder AB acquired a new stake in shares of Revolution Medicines in the fourth quarter worth $173,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the transaction, the insider now owns 441,564 shares in the company, valued at approximately $17,238,658.56. This trade represents a 2.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Margaret A. Horn sold 3,058 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the sale, the chief operating officer now owns 153,533 shares of the company’s stock, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,660 shares of company stock worth $650,406. Insiders own 8.00% of the company’s stock.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $36.56 on Tuesday. The business’s 50 day moving average price is $37.68 and its 200-day moving average price is $44.32. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40. The firm has a market capitalization of $6.80 billion, a PE ratio of -10.18 and a beta of 1.37.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). As a group, analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $59.00 price target on shares of Revolution Medicines in a report on Tuesday, April 8th. Stifel Nicolaus dropped their target price on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Wedbush reiterated an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a research report on Thursday, February 27th. UBS Group raised their price objective on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $66.67.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.